[1]
Gordon, K., Warren, R., Gottlieb, A., Blauvelt, A., Tha├ži, D., Poulin, Y., Boehnlein, M., Brock, F., Arendt, C. and Reich, K. 2020. Durable Efficacy of Certolizumab Pegol Dosed at 400 mg Every Two Weeks Over 128 Weeks in Patients with Plaque Psoriasis Enrolled in Three Phase 3 Trials (CIMPASI-1, CIMPASI-2, and CIMPACT). SKIN The Journal of Cutaneous Medicine. 4, 6 (Oct. 2020), s81. DOI:https://doi.org/10.25251/skin.4.supp.81.